Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics

PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a 420‐mg maintenance dose intravenously every 3 weeks. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Stephanie N., Lu, Tong, Jin, Jin Y., Li, Chunze, Girish, Sandhya, Melnikov, Fjodor, Badovinac Crnjevic, Tanja, Machackova, Zuzana, Restuccia, Eleonora, Kirschbrown, Whitney P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Modeling and Simulation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361934/
https://www.ncbi.nlm.nih.gov/pubmed/33719071
http://dx.doi.org/10.1002/jcph.1855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361934/
https://www.ncbi.nlm.nih.gov/pubmed/33719071
http://dx.doi.org/10.1002/jcph.1855

Ejemplares similares